Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of wound healing, scar reduction, scar prevention, and the treatment and prevention of wrinkles.
产品描述 | Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of wound healing, scar reduction, scar prevention, and the treatment and prevention of wrinkles. |
靶点活性 | EP2:0.19 nM (EC50) |
体外活性 | Aganepag (Compound 3) is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM. It shows no activity at EP4. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention[1]. |
别名 | AGN 210937 |
分子量 | 429.57 |
分子式 | C24H31NO4S |
CAS No. | 910562-18-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Aganepag 910562-18-4 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor AGN-210937 AGN 210937 AGN210937 Inhibitor inhibitor inhibit